Genet ics Analysis of Polymorphic Patterns in Candidate Genes in Israeli Patients with Prostate Cancer

Background: The precise genes involved in conferring prostate cancer risk in sporadic and familial cases are not fully known. Objectives: To evlauate the genetic profile within several candidate genes of unselected prostate cancer cases and to correlate this profile with disease parameters. Methods: Jewish Israeli prostate cancer patients (n=224) were genotyped for polymorphisms within candidate genes: p53, ER, VDR, GSTT1, CYP1A1, GSTP1, GSTM1, EPHX and HPC2/ELAC2, followed by analysis of the genotype with relevant clinical and pathologic parameters. Results: The EPHX gene His113 allele was detected in 21.4% (33/154) of patients in whom disease was diagnosed above 61 years, compared with 5.7% (4/70) in earlier onset disease (P< 0.001). Within the group of late-onset disease, the same allele was noted in 5.5% (2/36) with grade I tumors compared with 18% (34/188) with grade II and up (P = 0.004). All other tested polymorphisms were not associated with a distinct clinical or pathologic feature in a statistically significant manner. Conclusions: In Israeli prostate cancer patients, the EPHX His113 allele is seemingly associated with a more advanced, lateonset disease. These preliminary data need to be confirmed by a larger and more ethnically diverse study.

[1]  M. Marberger,et al.  Vitamin D receptor gene polymorphism and prostate cancer risk , 2002, The Prostate.

[2]  J. Stanford,et al.  A polymorphism in the CYP17 gene and risk of prostate cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[3]  K. Klinger,et al.  Germline mutations in the ribonuclease L gene in families showing linkage with HPC1 , 2002, Nature Genetics.

[4]  T. Beer,et al.  Association of codon 72 polymorphism of p53 with lower prostate cancer risk , 2001, The Prostate.

[5]  R. Eeles,et al.  Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. , 2001, Pharmacogenetics.

[6]  J. Trachtenberg,et al.  HPC2 variants and screen-detected prostate cancer. , 2001, American journal of human genetics.

[7]  J. Carpten,et al.  Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. , 2001, American journal of human genetics.

[8]  B. Green,et al.  Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. , 2000, Pharmacogenetics.

[9]  T. Rebbeck,et al.  Association of HPC2/ELAC2 genotypes and prostate cancer. , 2000, American journal of human genetics.

[10]  E. Goode,et al.  Analysis of chromosome 1q42.2-43 in 152 families with high risk of prostate cancer. , 1999, American journal of human genetics.

[11]  D. Grignon,et al.  p53 gene alterations in prostate cancer after radiation failure and their association with clinical outcome: a molecular and immunohistochemical analysis. , 1999, Pathology, research and practice.

[12]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[13]  P. Lin,et al.  p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  F. Oesch,et al.  Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. , 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[15]  D. Forman,et al.  Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. , 1997, Carcinogenesis.

[16]  B. Riggs Vitamin D-receptor genotypes and bone density. , 1997, The New England journal of medicine.

[17]  S. Shapiro,et al.  Family history and prostate cancer risk. , 1996, American journal of epidemiology.

[18]  Jack A. Taylor,et al.  Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer , 1996, Molecular carcinogenesis.

[19]  J. Mohler,et al.  Association of prostate cancer with vitamin D receptor gene polymorphism. , 1996, Cancer research.

[20]  R. Weaver,et al.  The immunohistochemical localization of drug‐metabolizing enzymes in prostate cancer , 1995, The Journal of pathology.

[21]  S. Anttila,et al.  Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility--a review. , 1995, Gene.

[22]  J. S. Sidhu,et al.  Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. , 1994, Human molecular genetics.